Eli Lilly signs research deal with AI-focused Genetic Leap
By Thomson ReutersSep 5, 2024 | 10:16 AM
(Reuters) – Eli Lilly has entered into a research deal with artificial intelligence-focused firm Genetic Leap for up to $409 million to develop genetic medicines, the latter said on Thursday.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shreya Biswas)
Comments